Aortic Stenosis
Conditions
Keywords
Aortic Stenosis, Myocardial efficiency
Brief summary
Background - Aortic valve stenosis (AS) is the most common heart valve disease among adults in the Western world with a prevalence of 3 % in people older than 75 years of age. AS usually deteriorates over time leading to heart failure, with high mortality if aortic valve replacement (AVR) is not performed. Thus optimal timing of AVR is crucial, but can be challenging. Increasing life expectancy in our society will augment the therapeutic and socio economic impact of AS disease on our health care system. Therefore, new techniques for monitoring asymptomatic AS patients are needed. A potential approach is monitoring of LV myocardial efficiency (mechanical work/oxygen consumption). These measures have been suggested to be involved in the progression of non-valvular heart failure and closely related to prognosis, but never applied in a larger population of patients with AS. At present there are no recognized pharmacological treatments of AS. It is known that beta-blocker treatment in non-valvular systolic heart failure reduce heart rate, improves LV myocardial efficiency and reduces mortality. However, in patients with AS, the effects of beta-blockers are unknown. Hypotheses - Treatment with the beta-blocker metoprolol succinate in patients with asymptomatic moderate to severe AS has beneficial effects on LV myocardial oxidative metabolism, myocardial efficiency and contractile function. Objectives - To investigate if beta-blocker treatment in patients with moderate to severe, asymptomatic AS has beneficial effects on LV myocardial efficiency, contractile function and physical performance. Design - A randomized double blind placebo controlled intervention trial. 40 patients with asymptomatic AS will be randomized to either per oral metoprolol succinate (N = 20) or placebo (N= 20) for 22 weeks. Primary objective - Changes in myocardial efficiency Secondary objectives - Myocardial oxygen consumption, Myocardial perfusion at rest, LV myocardial function, LVmass, Aortic valve area and transaortic valve velocities, 6 minute walking distance, N-terminal prohormone of brain natriuretic peptide, Quality of life (estimated by Minnesota living with heart failure questionnaire), LV wall stress Methods - Patients will undergo echocardiography (resting and exercise), \[11C\]acetate PET and cardiac magnetic resonance imaging.
Interventions
DRUGMetoprololsuccinate
DRUGPlacebo
Placebo
Sponsors
Aarhus University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aortic valve area ≤1,2 cm2 and/or transaortic maximal velocity (VmaxAO) of 3,0-5,0 m/s * Sinus rhythm \>60/min after 5 minutes of rest * LVEF \>≥50% * Male or female * Age 20-100 years old * Safe birth control management for women of childbearing potential. * Negative urine-HCG for women of childbearing potential * Ability to understand the written patient information and to give informed consent
Exclusion criteria
* Systolic BP \<100 mmHg after 5 minutes of rest * Left ventricular posterior wall thickness \>17 mm * Signs or history of major myocardial infarction and/or severe ischemic heart disease * Severe asthma or chronic obstructive pulmonary disease * New York Heart Association (NYHA) classification \> I due to AS * NYHA \> II due to non-cardiac causes * 2ᵒ or 3ᵒ atrioventricular block * Ongoing beta-blocker therapy * Ongoing verapamil or diltiazem therapy * Ongoing monoamine oxidase inhibitors therapy (except MAO-B-inhibitors) * Sick sinus syndrome * Atrial fibrillation or fluttering * Lack of stable sinus rhythm * Pheochromocytoma * Severe peripheral vascular disease * Intolerance of Metoprolol succinate or its excipients * Other disease or treatment making subject unsuitable for study participation * Intolerance of tracer used for \[11C\]acetate PET recordings * Participation in other intervention study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LV myocardial efficiency | Changes will be evaluated after an expected average of 22 weeks of treatment |
Secondary
| Measure | Time frame |
|---|---|
| LV perfusion | Changes will be evaluated after an expected average of 22 weeks of treatment |
| LV myocardial function | Changes will be evaluated after an expected average of 22 weeks of treatment |
| LVmass | Changes will be evaluated after an expected average of 22 weeks of treatment |
| Aortic valve area | Changes will be evaluated after an expected average of 22 weeks of treatment |
| LV oxygen consumption | Changes will be evaluated after an expected average of 22 weeks of treatment |
| 6 minute walking distance | Changes will be evaluated after an expected average of 22 weeks of treatment |
| N-terminal prohormone of brain natriuretic peptide | Changes will be evaluated after an expected average of 22 weeks of treatment |
| Quality of life - estimated by Minnesota living with heart failure questionnaire | Changes will be evaluated after an expected average of 22 weeks of treatment |
| LV wall stress | Changes will be evaluated after an expected average of 22 weeks of treatment |
| Transaortic valve velocities | Changes will be evaluated after an expected average of 22 weeks of treatment |
Countries
Denmark
Outcome results
None listed